

201424018A

厚生労働科学研究費補助金  
地域医療基盤開発推進研究事業

安全な薬物治療を促進する  
多職種間情報共有システムの開発に関する研究

平成26年度 総括研究報告書

研究代表者 森 本 剛

平成 27 (2015) 年 3 月

# 平成26年度 総括研究報告書

## 目 次

I. 平成26年度研究班員名簿	-----	1
II. 総括研究報告		
1. 安全な薬物治療を促進する多職種間情報共有システムの開発に関する研究 森本 剛	-----	2
III. 研究成果の刊行に関する一覧表	-----	6
IV. 研究成果の刊行物・別刷	-----	8

厚生労働科学研究費補助金  
(地域医療基盤開発推進研究事業)

安全な薬物治療を促進する  
多職種間情報共有システムの開発に関する研究

平成 26 年度研究班員名簿

区分	氏名	所属	職名
研究代表者	森本 剛	兵庫医科大学 医学部	教授
研究分担者	作間 未織	兵庫医科大学 医学部	講師
	太田 好紀	兵庫医科大学 医学部	講師
	湯坐 有希	東京都立小児総合医療センター	医長
研究協力者	中村 嗣	島根県立中央病院	部長

総括研究報告

安全な薬物治療を促進する  
多職種間情報共有システムの開発に関する研究

研究代表者 森本 剛 兵庫医科大学 医学部 臨床疫学 教授

研究要旨

JADE Study のデータを基に、薬剤性有害事象に関連するナレッジベースを作成した。このナレッジベースを基に、抗生剤投与中の患者に下痢が発生した際に、医師、看護師、薬剤師ら医療従事者に下痢の発生を知らせると共に、それら多職種医療従事者間で情報を共有する下痢アラートシステム（1）と、患者の腎機能を随時モニタリングし、腎機能の低い患者をハイリスク患者として多職種医療従事者間で共有すると共に、腎機能の低い患者にとってハイリスクな薬剤処方時にはアラートが発生し、腎機能に応じた推奨投与量が表示されるシステム（2）を開発した。開発したシステムを導入する前のプレデータとして、島根県立中央病院に該当期間中入院した全入院患者 3202 人を対象に、患者の基礎情報及び入院期間中の血液検査値を収集した。対象患者の総入院日数は 47465 日、年齢中央値が 68 歳で、男性が 3085 人（48%）であった。入院時クレアチニン値の中央値は 0.75mg/dl、入院期間中に腎機能が悪化した患者は 2587 人（51%）であった。

薬剤性有害事象に関連するハイリスク薬剤や、薬剤性有害事象の中でも頻度の高い症状や重症度の高い症状、患者や診療環境におけるリスクファクターを抽出することができた。

研究分担者

作間 未織  
（兵庫医科大学 医学部 講師）  
太田 好紀  
（兵庫医科大学 医学部 講師）  
湯坐 有希  
（東京都立小児総合医療センター 医長）

ムを用いて、薬剤性有害事象の発生しやすい状況やハイリスク患者、実際の発生状況を、多職種医療従事者間で迅速かつ円滑に共有するシステムを開発し、その結果、多職種間のコミュニケーションの向上が、薬剤性有害事象の防止、早期発見を可能にし、日常診療における医療安全推進に寄与するかどうかを検証することを目的とする。

A. 研究目的

本研究は、電子カルテやオーダリングシステ

## B. 研究方法

### (倫理面への配慮)

本研究は、JADE Studyの疫学データを分析してナレッジベースを作成し、それを基に多職種医療従事者間で迅速かつ円滑に薬剤性有害事象に関する情報を共有するシステムを開発し、電子カルテ・オーダリングシステムに導入する段階と、開発したシステム導入の効果を横断研究及び電子カルテシステムから抽出するデータの解析で検証する段階がある。

平成26年度はJADE Studyのデータを基に、薬剤性有害事象に関連するハイリスク薬剤や、薬剤性有害事象の中でも頻度の高い症状や重症度の高い症状、患者や診療環境におけるリスクファクターを抽出し、ナレッジベースを作成した。それを基に、ハイリスク薬剤の投与を受けている患者、薬剤性有害事象を高率で起こしやすい患者、薬剤性有害事象を疑う症状の出現などを抽出し、その情報を多職種医療従事者間で共有することを可能にするシステムを開発し、島根県立中央病院の統合病院情報システム（SHIMANE-IIMS）に導入できる準備を行った。

引き続き、前向きコホート研究を行い、多職種間情報共有システムの導入前後で、薬剤性有害事象やエラーに変化があるかどうかを評価するための準備を行った。

島根県立中央病院の小児科・産婦人科を除く全ての診療科に入院した15歳以上の全ての患者を対象とし、入院日から退院日までを観察する。研究期間は、対照群として、多職種間情報共有システムの導入前3ヶ月間と導入後の3ヶ月間として、多職種間情報共有システムの導入前においては、システムをバックグラウンドで走らせ

て、潜在的な介入機会を測定し、多職種間情報共有システムの導入後は、これらの介入機会の頻度を測定し、同時に介入前後における薬剤性有害事象の発生率を測定する。

主要アウトカムは薬剤性有害事象及びエラーとし、対象患者の基礎情報、採血検査データ、薬剤性有害事象を疑う症状、その重症度や罹病期間、入院中死亡、入院期間などのデータを、SHIMANE-IIMSが蓄積しているデータベースから抽出し、解析を行う。

さらに医療従事者を対象とする横断研究を実施し、多職種医療従事者間における情報把握の向上、コミュニケーションの向上と満足度、システムの使いやすさと受け入れ度、対照群では仮想シナリオを用いた情報共有システム不備による潜在的リスクを検証する。

### (倫理面への配慮)

本研究は通常の診療を行いながら、患者のデータを経時的に収集する観察研究であり、患者に対して直接的な介入は行わない。この研究を行うことで患者の診断や治療にマイナスの影響を及ぼすことは少なく、患者に健康上の不利益を与える可能性はない。逆に、本研究を実施することで患者の安全性がより高くなる可能性がある。

横断研究においても、研究施設の管理者が回答に接触することを防ぐために、研究施設の担当者からは切り離して実施する。

患者の診療データを扱うので、プライバシーの保護は厳重に行い、データの収集を行う施設とデータの解析を行う施設（兵庫医科大学）を分離し、データ収集施設から解析施設へのデー

タの送付時は患者個人の同定が不可能な形で行われる。この手法については、これまでのJADE Studyで十分な経験を有する。

本研究の施行に当たっては、兵庫医科大学及び島根県立中央病院における倫理委員会の承認を得た。また、本申請課題は最新の「人を対象とする医学系研究に関する倫理指針」（平成26年12月 文部科学省・厚生労働省）に厳正に則り施行した。」

### C. 研究結果

JADE Studyのデータを基に、薬剤性有害事象に関連するナレッジベースを作成した。このナレッジベースを基に、抗生剤投与中の患者に下痢が発生した際に、医師、看護師、薬剤師ら医療従事者に下痢の発生を知らせると共に、それら多職種医療従事者間で情報を共有する下痢アラートシステム (1) と、患者の腎機能を随時モニタリングし、腎機能の低い患者をハイリスク患者として多職種医療従事者間で共有すると共に、腎機能の低い患者にとってハイリスクな薬剤処方時にはアラートが発生し、腎機能に応じた推奨投与量が表示されるシステム (2) を開発した。開発したシステムを導入する前のプレデータとして、島根県立中央病院に該当期間中入院した全入院患者3202人を対象に、患者の基礎情報及び入院期間中の血液検査値を収集した。対象患者の総入院日数は47465日、年齢中央値が68歳で、男性が3085人 (48%) であった。入院時クレアチニン値の中央値は0.75mg/dl、入院期間中に腎機能が悪化した患者は2587人 (51%) であった。

さらに、これらの研究と平行して、医療従事者を対象とした質問紙表をこれまでの研究や共同研究者とのディスカッションを通じて開発し、横断研究に用いる準備を行った。

### D. 考察

薬剤性有害事象に関連するハイリスク薬剤や、薬剤性有害事象の中でも頻度の高い症状や重症度の高い症状、患者や診療環境におけるリスクファクターを抽出することができた。

JADE Studyを基に作成したナレッジベースから、抗生剤投与による下痢の発生と、腎機能低下患者へのハイリスク薬剤投与の頻度が多いことが明らかとなった。頻度の高いこれらの事象に注目し、抗生剤投与中の下痢発生と、腎機能低下患者の同定ならびに、それらの患者へのハイリスク薬剤投与について、多職種医療従事者間の情報共有をスムーズにするシステムを開発することができた。

これらの研究を通じて得られた知見を、27年度に予定されている医療従事者向けの横断研究による、受容性の解析と合わせて分析することにより、多職種間情報共有システムの有効性がより一般化可能な形で提案できると考えられる。

### E. 結論

JADE Studyを基に作成したナレッジベースから、抗生剤投与による下痢の発生と、腎機能低下患者へのハイリスク薬剤投与の頻度が多いことが明らかとなった。頻度の高いこれらの事象に注目し、抗生剤投与中の下痢発生と、腎機能

低下患者の同定ならびに、それらの患者へのハイリスク薬剤投与について、多職種医療従事者間の情報共有をスムーズにするシステムを開発した。

これらの研究を通じて得られた知見と医療従事者向けの横断研究による、受容性の解析と合わせて分析することにより、多職種間情報共有システムの有効性がより一般化可能な形で提案できると考えられる。

## F. 健康危険情報

なし

## G. 研究発表

### 1. 論文発表

1) Morimoto T. Investigating quality of care in cardiovascular medicine. *Circ J* 2015; 79:966-8.

2) Khurelbat D, Dorj G, Bayarsaikhan E, Chimedsuren M, Sanjjav T, Morimoto T., Morley M, Morley K. Prevalence estimates of standard drugs in Mongolia using a random sample survey. *Springerplus* 2014;3:709.

3) Boeker EB, Ram K, Klopotoska JE, de Boer M, Creus MT, de Andres A, Sakuma M. Morimoto T., Boormeester MA, Dijkgraaf MG. An Individual Patient Data Meta-Analysis on Factors Associated with Adverse Drug Events in Surgical and Nonsurgical Inpatients. *Br J Clin Pharmacol* 2015;79:548-57.

4) Sakuma M., Ida H, Nakamura T, Ohta Y., Yamamoto K, Seki S, Hiroi K, Kikuchi K, Nakayama K, Bates DW, Morimoto T. Adverse drug events and medication errors in Japanese pediatric inpatients: A retrospective cohort study. *BMJ Qual Saf* 2014;23:830-7.

5) Ohta Y., Sakuma M., Koike K, Bates DW, Morimoto T. Influence of adverse drug events on morbidity and mortality in intensive care units: the JADE study. *Int J Qual Health Care* 2014;26:573-8.

2. 学会発表

1) Ohta Y., Sakuma M., Bates DW, Morimoto T. The epidemiology of operation related medical errors in inpatients in Japan: the JET Study. *35th International Symposium on Intensive Care and Emergency Medicine*, Brussels, Belgium. March 17-20, 2015.

### 2. 学会発表

2) Morimoto T., Sakuma M., Ohta Y., Bates DW. Incidence and nature of injuries due to medical care in Japan: the JET Study. *31th International Conference of the International Society for Quality in Health Care*, Rio de Janeiro, Brazil. October 5-8, 2014.

3) Sakuma M., Ohta Y., Bates DW, Morimoto T. The implementation of decision support system for reducing adverse drug events and medication errors in Japanese inpatients: the JADE Study. *31th International Conference of the International Society for Quality in Health Care*, Rio de Janeiro, Brazil. October 5-8, 2014.

5

4) Ohta Y, Sakuma M, Bates DW, Morimoto T.  
 The epidemiology of operation related adverse events in inpatients: the JET Study. *31th International Conference of the International Society for Quality in Health Care*, Rio de Janeiro, Brazil. October 5-8, 201

1. 特許取得  
なし
2. 実用新案登録  
なし
3. その他  
なし

H. 知的財産権の出願・登録状況  
 (予定を含む)

研究成果の刊行に関する一覧表

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
<u>Morimoto T</u>	Investigating quality of care in cardiovascular medicine	Circ J	79	966-8	2015
Khurelbat D, Dorj G, Bayarsaikhan E, Chimedsuren M, Sanjjav T, <u>Morimoto T</u> , Morley M, Morley K	Prevalence estimates of substandard drugs in Mongolia using a random sample survey	Springerplus	3	709	2014



Boeker EB, Ram K, Klopotoska JE, de Boer M, Creus MT, de Andres A, <b><u>Sakuma M</u></b> , <b><u>Morimoto T</u></b> , Boermeester MA, Dijkgraaf MG	An Individual Patient Data Meta-Analysis on Factors Associated with Adverse Drug Events in Surgical and Nonsurgical Inpatients	Br J Clin Pharmacol	79	548-57	2015
<b><u>Sakuma M</u></b> , Ida H, Nakamura T, <b><u>Ohta Y</u></b> , Yamamoto K, Seki S, Hiroi K, Kikuchi K, Nakayama K, Bates DW, <b><u>Morimoto T</u></b>	Adverse drug events and medication errors in Japanese pediatric inpatients: A retrospective cohort study	BMJ Qual Saf	23	830-7	2014
<b><u>Ohta Y</u></b> , <b><u>Sakuma M</u></b> , Koike K, Bates DW, <b><u>Morimoto T</u></b>	Influence of adverse drug events on morbidity and mortality in intensive care units: the JADE study	Int J Qual Health Care	26	573-8	2014



## Investigating the Quality of Care in Cardiovascular Medicine

Takeshi Morimoto, MD, PhD

Quality of care should be a core value within modern healthcare systems. Cardiovascular medicine is the one of the most advanced medical subspecialties in providing evidence-based, state-of-the-art practices in developed countries. In spite of this, in the USA, medical interventions, not diseases themselves, resulted in approximately 44,000–98,000 fatalities per year and roughly 1 in 100 patients admitted to hospitals died because of a medical intervention.<sup>1</sup> The risk of undergoing medical care is considered the worst compared to many industries and other human activities (Figure 1).<sup>2</sup> We are aware that medicine has saved many more lives in history; therefore, we have conducted much research in both basic and clinical sciences to maximize saved lives and minimize injuries from medical interventions. Much clinical research has attempted to explore the association between disease management and patient outcomes, whereas basic science research has investigated the principles of such association, even before the association has been identified.

### Article p1058

Clinical researchers investigate the association between disease management, such as drugs, devices, diagnostic tools, severity classification, and symptom gradients, and patient outcomes, including some surrogate measures. Well-conducted research has provided data relevant to clinical practice, and many more patients who were not investigated under the researches also receive the benefit of such proven disease management. However, who would not enjoy the state-of-the-art practice? Of course, there are other factors that become obstacles to the dissemination of state-of-the-art practice, such as lack of funds or a lower educational level of patients and the general public. Japan is a unique country among the developed countries in that, within its healthcare system, all patients can receive ideal standard practice under universal healthcare insurance with limited payment. If there is any variation in disease management between patients, however, the reasons




Figure 1. Quality metrics of major industries and human activities. (Adapted with permission from Amalberti R, et al.<sup>2</sup>)

The opinions expressed in this article are not necessarily those of the editors or of the Japanese Circulation Society.

Received March 31, 2015; accepted March 31, 2015; released online April 9, 2015

Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan

Mailing address: Takeshi Morimoto, MD, PhD, MPH, Department of Clinical Epidemiology, Hyogo College of Medicine, 1-1 Mukogawa, Nishinomiya 663-8501, Japan. E-mail: tm@hyo-med.ac.jp

ISSN-1346-9843 doi:10.1253/circj.CJ-15-0371

All rights are reserved to the Japanese Circulation Society. For permissions, please e-mail: cj@j-circ.or.jp




Figure 2. Components of quality of care and their obstacles.

should be considered.

It is not necessarily the case that similar patients received the same care. Some of the reasons are differences in the diseases themselves or patient preferences, but one significant reason is variation, which we term "quality of care".<sup>3</sup> Typically, quality of care is determined and measured by (1) structure, (2) process, and (3) outcome.<sup>3</sup> To clarify the issues in quality of care, I have differentiated surrogates from outcomes, and imputed governance and healthcare regulations (Figure 2). The definitions of quality of care and its components are difficult to determine, and several definitions have been reported, but one definition of quality care is "the degree to which health services for individuals and populations increase the likelihood of desired health outcomes and are consistent with current professional knowledge".<sup>4</sup> Structure is defined as "the facilities, equipment, services, and manpower available for care and the credentials and qualifications of the health care professionals involved".<sup>5</sup> How is structure determined? Governance and healthcare regulations typically determine the components of structure, such as people and equipment invested. Process is defined as "content of care", in other words, "how the patient is moved into, through, and out of the health care system and the services that are provided during the care episode".<sup>5</sup> Outcomes vary widely from biological changes in disease to physical function or satisfaction of family members, but we should be aware that some of the commonly utilized outcome measures are surrogates, such as the naming of physical conditions or change in blood components (vs. avoidance of cardiovascular events).

Many clinical researchers have tried to provide evidence for the associations between process and outcomes. Relationships between the use of drugs or devices and difference in incidences of diseases are typical examples. For instance, we have explored the association of the unrestricted use of drug-eluting stents (DES) and major cardiovascular events in patients with acute coronary syndrome (ACS).<sup>6</sup> In that study, the process was the unrestricted use of DES in patients with ACS and the

outcomes were all-cause death, myocardial infarction, definite stent thrombosis, stroke, any coronary revascularization, and major bleeding. It has been claimed that the unrestricted use of DES for patients with ACS is safe. Thus, can we say that the quality of care of patients with ACS should improve if we used DES rather than other treatment modalities? This phrase may or may not be true. There are many alternative explanations for particular observations, and no one can know the absolute truth. No observation is free from bias and confounders, even in well-conducted randomized controlled trials. There are also many issues with the lack of evidence for associations between process and outcomes, as well as with associations between frequently used surrogates and patient-oriented outcomes (Figure 2). We have to recognize the many limitations inherent to any clinical research. Thus, in the future, we should conduct more solid clinical research to confirm previous observed findings and explore new associations to improve the quality of care.

Expanding the scope from the typical clinical research (red-bordered square in Figure 2), we should be aware of other important components in the quality of care, namely structure and its determinants (governance and healthcare regulations). If the findings that suggest the unrestricted use of DES improved the long-term outcomes in patients with ACS are true, does the quality of care for such patients improve? The answer is no. If DES use were not approved for ACS patients? If the charge was not reimbursed by the insurance? If the ACS patient was not diagnosed correctly? If such patients cannot meet capable interventional cardiologists within the appropriate time? If radiology technicians are not available when such patients arrived? If, if, if... We are now aware of the importance of structure, governance, and healthcare systems to achieve state-of-the-art medical excellence in real-world medicine.

In this issue of the Journal, Tomoike and colleagues<sup>7</sup> provide an excellent view on the geographical distribution of medical resources in cardiovascular medicine as part of a Japanese Circulation Society project. Readers should keep in

mind that this report was based on a limited number of hospitals that responded to the survey, which the authors note as a limitation. However, the authors did their best to compare their data with the national census. It is also vital to keep in mind that urban areas had more resources whereas rural areas had fewer even in the same prefecture. The authors compared the resources in cardiovascular medicine to the population and obtained Gini coefficients. The Gini coefficient is a well-known scale of inequality, which ranges from 0 (perfect equality, ie, everyone has the same resources) to 1 (perfect inequality, ie, only one has all resources while all others have none).<sup>8</sup> To better explain this, I will use a monetary example. The Gini coefficient of wealth in Japan was 0.32 in 2008 and that of the USA was 0.41 in 2010.<sup>9</sup> Those of African countries were generally greater than 0.5.<sup>9</sup> The Gini coefficient of wealth in Finland, a country well known for higher equality in health-care, was still 0.28 in 2010. Compared with the index of wealth distribution, cardiovascular medicine generally provided equal practice, by comparison of the Gini coefficients, at approximately 0.15 among the surveyed hospitals in Japan. The study also sheds light on an area that needs improvement. The Gini coefficients of pediatric care were greater than 0.25.

These data represent one aspect of the structure of cardiovascular medicine in Japan. To improve the structure, good governance and good healthcare regulations are needed. As shown in the article, the equality of healthcare is generally good in Japan, but we still need the support of healthcare regulations. The breakdown of structure occurs if governance is poor or if age deterioration is allowed to occur. We frequently encounter a mismatch between structure and process in many aspects of reality. This article does not demonstrate

the association between structure and process or outcomes. Therefore, well-designed clinical research studies to confirm the relationship between structure and true outcomes are strongly needed.

### Conflict of Interest

Nothing to declare.

### References

1. Institute of Medicine. *To err is human: Building a safer health system*. Washington, DC: National Academies Press, 2000.
2. Amalberti R, Auroy Y, Berwick D, Barach P. Five system barriers to achieving ultrasafe health care. *Ann Intern Med* 2005; **142**: 756–764.
3. Hammermeister KE, Shroyer AL, Sethi GK, Grover FL. Why it is important to demonstrate linkages between outcomes of care and processes and structures of care. *Med Care* 1995; **33**(Suppl): OS5–OS16.
4. Lohr KN, Schroeder SA. A strategy for quality assurance in Medicare. *N Engl J Med* 1990; **322**: 707–712.
5. Council of Medical Service. Quality of care. *JAMA* 1986; **256**: 1032–1034.
6. Kawaji T, Shiomi H, Morimoto T, Tamura T, Nishikawa R, Yano M, et al. Long-term efficacy and safety outcomes after unrestricted use of drug-eluting stents in patients with acute coronary syndrome: Mortality and major bleeding in a single-center registry. *Circ J* 2014; **78**: 1628–1635.
7. Tomoike H, Yokoyama H, Sumita Y, Hanai S, Kada A, Okamura T, et al. Nationwide distribution of cardiovascular practice in Japan: Results of Japanese Circulation Society 2010 annual survey. *Circ J* 2015; **79**: 1058–1067.
8. Moskowitz CS, Seshan VE, Riedel ER, Begg CB. Estimating the empirical Lorenz curve and Gini coefficient in the presence of error with nested data. *Stat Med* 2008; **27**: 3191–3208.
9. The World Bank. Gini index. <http://data.worldbank.org/indicator/SI.POV.GINI>. (accessed March 19, 2015).

RESEARCH

Open Access

# Prevalence estimates of substandard drugs in Mongolia using a random sample survey

Daariimaa Khurelbat<sup>1</sup>, Gereltuya Dorj<sup>2</sup>, Enkhtuul Bayarsaikhan<sup>1</sup>, Munkhdelger Chimedsuren<sup>3</sup>, Tsetsegmaa Sanjjav<sup>4</sup>, Takeshi Morimoto<sup>5</sup>, Michael Morley<sup>6</sup> and Katharine Morley<sup>7\*</sup>

## Abstract

To determine the prevalence of substandard drugs in urban (Ulaanbaatar) and rural (selected provinces) areas of Mongolia, samples of 9 common, therapeutically important drugs were collected from randomly selected drug outlets in Ulaanbaatar and 4 rural provinces by "mystery shoppers". Samples were analyzed by visual inspection, registration status, and biochemical analysis. Samples failing to meet all Pharmacopeia quality tests were considered substandard.

In the rural provinces, 69 out of 388 samples were substandard, giving an estimated prevalence of substandard drugs of 17.8% (95% CI: 14.1-22.0). There were 85 unregistered samples, giving a prevalence estimate of unregistered drugs of 21.9% (95% CI: 17.9-26.3). In the urban Ulaanbaatar districts, 112 out of 848 samples were substandard, giving an estimated prevalence of substandard drugs of 13.2% (95% CI: 11.0-15.7). There were 150 unregistered samples, giving a prevalence estimate of unregistered drugs of 17.7% (95% CI: 15.2-20.4).

In the rural provinces, 35 out of 85 (41.2%) unregistered samples were substandard; whereas 34 out of 303 (11.2%) registered samples were substandard. ( $p < 0.0001$ ) In the urban districts, 18 out of 150 (12.0%) unregistered samples were substandard, whereas 94 out of 698 registered were substandard. (13.5%) ( $p = 0.6$ ).

The prevalence of substandard and unregistered drugs is higher in rural provinces. There is a significant association between substandard and unregistered drugs in the provinces but not in the urban districts. The underlying causes for substandard drugs need to be further investigated in order to help formulate strategies to improve pharmacovigilance and the drug supply quality in Mongolia.

**Keywords:** Medication quality; Substandard; Falsified; Patient safety; Asia; Developing countries

## Background

Poor quality drugs have been increasingly recognized as a global public health threat because they have the potential to result in inadequate treatment, cause adverse effects from toxic ingredients, and promote drug resistance. The nomenclature of the categories of poor quality medications can be confusing. The World Health Organization recently chose to group all categories together as "SSFFC": substandard, spurious, falsely-labeled, falsified, and counterfeit. Revision of these categories as: "substandard" - drugs that for unintentional reasons do not meet the legally required quality specifications of a country's regulators, "unregistered" - drugs that do not have the legally required marketing authorization from the country's regulators, and

"falsified" - drugs that are unlawful, and violate the regulators quality specifications, with criminal intent was subsequently suggested (Attaran et al. 2012). Fernandez, et al. raise the issue that a genuine drug found to have an insufficient amount of an active ingredient could be substandard or degraded (Fernandez et al. 2011), indicating poor quality drugs can result from issues in production or external factors such as environmental conditions, impacting quality after distribution.

The true extent of the problem is difficult to ascertain. Reasons for this include the difficulty and expense in performing a methodologically sound study, reluctance of governments to disclose information and the fact that many of the effects on patients are difficult to detect and hidden in other public health statistics (Cockburn et al. 2005). In his 2010 article, Newton states there is an urgent need for data of sufficient sample size, with random

\* Correspondence: kemorley@mgh.harvard.edu

<sup>7</sup>Department of Medicine, Harvard University, Boston, MA, USA

Full list of author information is available at the end of the article

sampling design to reliably estimate the prevalence of poor quality medicines (Newton, et al. 2010). Literature reviews of prevalence studies on falsified/substandard drugs report that the percentage of substandard drugs in various Asian and African countries range from 8–46% (Caudron et al. 2008), and the median prevalence of substandard/falsified medicines was 28.5% (range 11–48%) (Almuzaini et al. 2013). The World Health Organization (WHO) conducted a survey on the quality of selected anti-malarial medication in 6 sub-Saharan African countries, which found that 28.5% of the samples failed to meet testing requirements, with 11.6% having extreme deviations, and therefore likely to have negative health implications (Sabartova et al. 2011a). Another WHO survey was conducted on the quality of anti-tuberculosis medications in Russia, and found 11.3% of the samples failed to meet study specifications, with 1.0% having extreme deviations (Sabartova et al. 2011b). In 1999, WHO conducted a survey of drug quality in Myanmar and Vietnam, and found that 16% of the samples did not meet all specifications of testing (Wondemagegnehu 1999).

Between 2004–2006 the pharmaceutical procurement system in Mongolia underwent decentralization, and is now 100% privatized. In the current system, the Division of Pharmaceutical and Medical Devices, Mongolian Ministry of Health (MoH) is responsible for the policy, planning and regulatory affairs in providing pharmaceutical care in Mongolia. The special licenses for manufacturing, importing, purchasing pharmaceuticals and medical devices are granted by the Special Permission Committee of the MoH. Drugs are distributed through drug wholesalers and retail drug outlets (community pharmacies and revolving drug funds (RDF)). Wholesalers can import and procure drugs with an approval and special permission from the Mongolian Minister of Health. In 2011, there were 158 registered drug wholesaling companies and 42 local drug manufacturing companies, some of which act as both wholesalers and retailers. Approximately 85% of all drugs are imported from other countries, primarily Russia and India, followed by Germany, Slovenia and China.

Poor quality drugs have been a concern in Mongolia, supported by the findings from a 2006 study on unregistered, falsified and substandard drugs (Mongolia Ministry of Health 2006). Using convenience sampling methods, 225 samples were collected from 40 drug outlets around the country, 55 of which were felt to be “suspicious” and were sent for further testing. Sixteen of these were felt to be “inconsistent” and 8 were possibly counterfeit. A 2008 study by Tsetsegmaa found that 11 of the 16 medications reported in the surveillance were substandard (Tsetsegmaa 2008). In a 2009 report, lack of knowledge about the effectiveness of drug quality monitoring in Mongolia was reported as a gap that should be a priority for further investigation (Abdelkrim 2009).

This research study was undertaken to address these concerns, and provide data of good methodological quality to accurately determine the prevalence of substandard drugs in the rural and urban areas of Mongolia after the decentralization and privatization of the Mongolian pharmaceutical system. This information will be of value to Mongolian policy makers, public health officials and pharmaceutical practitioners to reliably determine the extent of the problem, and then can serve as a valid comparison for future studies to evaluate interventions to improve the drug supply quality. It will also help guide further research to better understand the health impact of poor quality medications in Mongolia.

## Methods

### Site selection

Mongolia is a landlocked country in north central Asia, with 21 rural provinces, plus 1 municipality, the capital city of Ulaanbaatar where over 60% of the population lives. Because the conditions in rural provinces vary greatly from the urban area of Ulaanbaatar, samples were collected, analyzed, and reported independently. Samples for this study were collected from 4 districts in Ulaanbaatar (Chingeltei, Khan-Uul, Bayanzurkh, and Songinokhair) and 4 rural provinces (Bayan-Ugii, Dornogobi, Selenge, and Umnugobi) representing the main geographic regions of the country. Samples were obtained from the different types of drug outlets in the provinces: Revolving Drug Fund (RDF- a government outlet), retail pharmacy outlets, and wholesalers. In Ulaanbaatar districts, samples were only obtained from retail pharmacy outlets and wholesalers, as RDF outlets are only present in the provinces. Samples from unofficial drug outlets and the informal market were not included in this study.

Medications included in the study were selected based on high therapeutic importance and utilization based on discussions with local experts from Schools of Pharmacy, Public Health, and Mongolian National University of Medical Sciences. They are all on the Essential Drug List and available with or without a prescription. All samples were tablets or capsules and include antimicrobials (ampicillin, amoxicillin, co-trimoxazole, metronidazole, doxycycline, nystatin), analgesics (paracetamol and ibuprofen), and bromhexin, a commonly used medication for respiratory illness (Table 1).

### Sample size calculation

Prevalence studies from other countries indicate a wide range of substandard drugs, 8–46% (Caudron et al. 2008), and 11–48% (Almuzaini et al. 2013). Based on this information and the previous studies of falsified/substandard drugs in Mongolia, we targeted our sample size to detect at least a 5% prevalence (alpha of 0.05 and beta of 0.9). This calculation was 134 samples for each drug (1206 for

**Table 1 Drugs in study population**

Name of drug	Dosage form	Pharmacopeia reference
Metronidazole	250 mg/tab	Mongolian National Pharmacopeia 2011 Pharmacopeia of the People's Republic of China 2005. Vol. II,
Nystatin	500000 ID/tab	British Pharmacopeia 2001, Vol.2
Ibuprofen	400 mg/tab	Mongolian National Pharmacopeia 2011 Pharmacopeia of the People's Republic of China 2005. Vol. II,
Co-trimoxazole	480 mg/tab	Mongolian National Standard-MNS 6149-2010
Amoxicillin	500 mg/cap	Mongolian National Pharmacopeia 2011
Paracetamol	500 mg/tab	Mongolian National Pharmacopeia 2011 Pharmacopeia of the People's Republic of China 2005. Vol. II,
Ampicillin	500 mg/cap	British Pharmacopeia 2001, Vol. 2 Mongolian National Pharmacopeia 2011 USP 23
Bromhexin	8 mg/tab	Mongolian National Pharmacopeia 2011 Pharmacopeia of the People's Republic of China 2005. Vol. II,
Doxycycline	100 mg/cap	Mongolian National Standard-MNS 5776-2007 Pharmacopeia of the People's Republic of China 2005. Vol. II,

all drug types combined) distributed among the provinces or districts. In order to detect a 10% prevalence, the sample size needed was 67 (603 combined) and 15% prevalence was 38 samples (342 combined).

#### Sampling techniques

The sampling strategy included weighting the sample size by population and the number of the types of drug outlets in the province or district. Drug outlets to be sampled were selected randomly.

A sample was defined as 100 dosage units (tablet or capsule) of a given drug of the same lot number purchased in blister packs of 10 dosage units.

Samples were collected from the 4 provinces between May 2012 and September 2012 and from the 4 Ulaanbaatar

districts between July 2012 and March 2013 by "mystery shoppers". These were trained field workers, who presented themselves as local customers, and followed the study protocol for obtaining drug samples based on recommended sampling techniques (Newton et al. 2009). If they were unable to purchase the necessary quantity for a complete sample from one batch or lot, this was noted and attempts were made to purchase it from another randomly selected outlet of the same type. Collected samples were placed in a box, then transported to and stored in lockers at the School of Pharmacy, Mongolian National University of Medical Sciences. The transport box and lockers met the temperature and humidity requires of the WHO Guidelines for the Sampling of Pharmaceutical Products, and were accessible only by the main study investigator.

#### Sample analysis

Sample analysis for each sample consisted of visual inspection of the packaging and labeling, and determination of registration status, expiration date, country of manufacture, biochemical analysis, and company of manufacture. An online database developed by the Ministry of Health in Mongolia (Licemed) and archive documents from the registration of drugs were used to complete the visual inspection. The database includes information such as size, color, labeling and numbers of the packages and labeling. In addition, the WHO guideline for the Development of Measures to Combat Counterfeit Drugs was used. (World Health Organization 1999) A sample was considered suspicious if the package and labeling was not consistent with registered information for that drug and manufacturer. Samples with suspicious packaging and labeling were sent to the manufacturers for confirmation. If the manufacturer confirmed that it was their product, the sample was considered acceptable.

The registration status of all samples was determined by visual inspection of the packaging, and then confirmed using the drug registration archives at the Mongolian Ministry of Health. Registration was not considered a requirement for determining whether or not a sample was substandard.

Drug samples underwent biochemical analysis by 1 of 3 laboratories in Mongolia: Drug and Bio-preparation Central Laboratory of Specialized Professional Inspection Agency (SPIA); Drug Control Laboratory, School of Pharmacy, Mongolian National University of Medical Sciences; and the Drug Testing Laboratory "Monos Group". These laboratories are accredited by the Standardization and Technical Regulatory Office of the Centre for Standardization and Measurement in Mongolia, which is responsible for the technical standards in local production and quality control. The Pharmacopoeias were chosen according to the country of origin of the sample or specification requirements of the manufacturer (Table 1). (British

Pharmacopoeia 2001, Mongolian Pharmacopoeia 2011, Pharmacopoeia of the People's Republic of China 2005). These requirements vary by drug, and include 8–11 of the following tests: appearance, assay, disintegration, dissolution, hardness, identification, irradiance absorption, water, friability, weight average and weight variation (Table 2). The qualitative analysis included: 1). visual inspection of package and labeling, 2). characteristics of the sample (appearance, odor, color dosage form), 3). uniformity of weight, disintegration, and dissolution, 4). identification of components by chemical reaction, and thin layer chromatography, spectrum analysis on UV spectrophotometer and IR spectrophotometer. Quantitative analysis included assay of active compounds by spectrophotometric, titrometric and chromatographic methods. A sample was considered to be substandard if it failed to pass all required tests for the drug required by the article requirements in the Pharmacopoeia used, that is, if the sample failed one or more of the required tests it was considered substandard.

#### Ethics approval

Ethics approval was obtained from the World Health Organization Ethics Review Committee and the Medical Ethics Committee of the Ministry of Health, Mongolia.

#### Statistical analyses

Measurements were presented as numbers and percentages with 95% confidence intervals (CIs), and were compared with the chi-square test or Fisher's exact test. P values <0.05 were regarded as statistically significant.

**Table 2 Sample analysis definitions**

Test	Definition
Appearance	Clean, smooth surface and uniform color of tablet or capsule
Friction and substantial	Tablet crushing strength
Weight average	Average weight of 20 tablets
Weight variation	Difference between the weight of the content of each solid form and the average weight of solid forms
Disintegration	Disintegration or disbursement of solid preparations into fragments or particles in a liquid medium
Dissolution	Rate and degree of dissolution of active ingredients in liquid medium
Content uniformity	Contents of single ingredient solid preparations
Water (Loss on drying)	Determine water loss on drying
Identification	Verify identity by visual inspection
Irradiance absorption	Absorbance in the ultraviolet region
Assay	Determine content of active ingredients

## Results

### Description of sample and analysis results

#### Sample description

The number of samples collected for this study was 388 from the rural provinces and 848 from the urban districts of Ulaanbaatar. The distribution of the samples based on location by drug outlet type is presented in Table 3, and location by drug in Table 4.

#### Sample inspection

Out of 388 samples from the rural provinces, only 3 were found to be past expiration date. There were 4 others that expired within the data collection period of May to August 2012, so may have recently expired. Out of 848 samples from the Ulaanbaatar districts, none were found to be past expiration date.

On initial inspection, 22 drug samples from the rural provinces and urban districts combined were found to have variation in the packaging and labeling of the drugs when compared with the products registered in Mongolia. Upon review by the manufacturer, all 22 were found to be acceptable or meeting standards due to packaging updates.

#### Biochemical sample analysis

Failure to pass the assay test (e.g. amount of required ingredients fell outside range of Pharmacopoeia standards) was the most common reason that a sample was found to be substandard. Failure to pass this test indicates that the sample did not meet the threshold requirements regarding amount of drug present and does not give any information about the degree or direction of deviation from the required standard (Table 5). In the provincial group, 51 out of 388 (13.4%, 95% CI: 9.9-16.9) samples failed the assay test. The other common reasons were weight variation and

**Table 3 Number of samples by location and drug outlet type**

	Wholesale		Retail		RDF*		Total	
	N	%	N	%	N	%	N	%
<b>Rural provinces</b>								
Bayan-Ulgii	15	3.9	77	19.8	34	8.8	126	32.5
Dornogobi	14	3.6	30	7.7	36	9.3	80	20.6
Selenge	12	3.1	52	13.4	58	14.9	122	31.4
Umnugobi	10	2.6	27	7.0	23	5.9	60	15.5
<b>All provinces</b>	<b>51</b>	<b>13.1</b>	<b>186</b>	<b>47.9</b>	<b>151</b>	<b>38.9</b>	<b>388</b>	<b>100</b>
<b>Urban districts</b>								
Bayanzurkh	41	4.8	248	29.2	NA	NA	289	34.1
Chingeltei	50	5.9	111	13.1	NA	NA	161	19.0
Khan-Uul	32	3.8	97	11.4	NA	NA	129	15.2
Songinokhairkhan	26	3.1	243	28.7	NA	NA	269	31.7
<b>All districts</b>	<b>149</b>	<b>17.6</b>	<b>699</b>	<b>82.4</b>	<b>NA</b>	<b>NA</b>	<b>848</b>	<b>100</b>

\*RDF: Revolving Drug Fund (government outlet).



**Table 4 Number of samples by drug and location**

	Amoxicillin		Ampicillin		Bromhexin		Co-trimoxazole		Doxycycline		Ibuprofen		Metronidazole		Nystatin		Paracetamol		Total		
	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	
<b>Rural province</b>																					
Bayan-Ulgii	17	4.4	14	3.6	13	3.4	17	4.4	10	2.6	13	3.4	14	3.6	15	3.9	13	3.4	126	32.5	
Dornogobi	11	2.8	8	2.1	8	2.1	10	2.6	10	2.6	8	2.1	8	2.1	9	2.3	8	2.1	80	20.6	
Selenge	12	3.1	13	3.4	14	3.6	14	3.6	14	3.6	13	3.4	13	3.4	18	4.6	11	2.8	122	31.4	
Umnugobi	6	1.5	5	1.3	6	1.5	6	1.5	9	2.3	9	2.3	6	1.5	7	1.8	6	1.5	60	15.5	
<b>All provinces</b>	<b>46</b>	<b>12</b>	<b>40</b>	<b>10</b>	<b>41</b>	<b>11</b>	<b>47</b>	<b>12</b>	<b>43</b>	<b>11</b>	<b>43</b>	<b>11</b>	<b>41</b>	<b>11</b>	<b>49</b>	<b>13</b>	<b>38</b>	<b>10</b>	<b>388</b>	<b>100</b>	
<b>Urban district</b>																					
Bayanzurkh	33	3.9	37	4.4	41	4.8	30	3.5	27	3.2	31	3.7	37	4.4	31	3.7	22	2.6	289	34.1	
Chingeltei	24	2.8	15	1.8	13	1.5	18	2.1	17	2.0	20	2.4	21	2.5	19	2.2	14	1.7	161	19.0	
Khan-Uul	14	1.7	15	1.8	19	2.2	14	1.7	11	1.3	12	1.4	16	1.9	16	1.9	12	1.4	129	15.2	
Songinokhairkhan	30	3.5	27	3.2	33	3.9	33	3.9	28	3.3	32	3.8	35	4.1	34	4.0	17	2	269	31.7	
<b>All districts</b>	<b>101</b>	<b>11.9</b>	<b>94</b>	<b>11.1</b>	<b>106</b>	<b>12.5</b>	<b>95</b>	<b>11.2</b>	<b>83</b>	<b>9.8</b>	<b>95</b>	<b>11.2</b>	<b>109</b>	<b>12.9</b>	<b>100</b>	<b>11.8</b>	<b>65</b>	<b>7.7</b>	<b>848</b>	<b>100</b>	

**Table 5 Number of samples failing assay by location**

	Rural			Urban		
	N	%	95% CI*	N	%	95% CI*
Failed assay	51	13.1	9.9, 16.9	55	6.5	4.9, 8.4
Passed assay	337	86.9	83.1, 90.1	793	93.5	91.6, 95.1
<b>Total</b>	<b>388</b>	<b>100</b>		<b>848</b>	<b>100</b>	

\*CI: confidence interval

weight average. There were a few samples failing tests for dissolution, disintegration and friction (Table 6). In the Ulaanbaatar district samples, 55 out of 848 (6.6%, 95% CI: 4.9- 8.4) failed the assay test (Table 5). The other common reasons were disintegration and dissolution. There were a few samples that failed the following tests weight variation, weight average, and friction (Table 7).

#### Prevalence of substandard drugs

##### Rural provinces

Out of 388 samples collected from all 4 rural provinces, 69 were classified as substandard. This gives a substandard drug prevalence rate of 17.8% (95% CI: 14.1-22.0) in the rural provinces (Table 8).

##### Urban districts

Out of 848 samples collected from all 4 urban districts of Ulaanbaatar, 112 were classified as substandard. This gives a prevalence rate of 13.2% (95% CI: 11.0-15.7) substandard drugs in the urban districts of Ulaanbaatar (Table 8).

#### Registration status

##### Rural provinces

Out of 388 samples collected from the 4 provinces, 85 were unregistered. This gives a prevalence estimate of unregistered drugs in the provinces of 21.9%. (95% CI: 18.0-26.3) (Table 9). Out of the 85 unregistered samples, 35 were substandard (41.2%), compared with 34 substandard samples out of the 303 registered samples (11.2%). This is a statistically significant difference ( $p < 0.0001$ ) (Table 10).

##### Districts of Ulaanbaatar

Out of 848 samples, collected from the 4 districts of Ulaanbaatar, 150 were unregistered. This gives a prevalence estimate of unregistered drugs in the Ulaanbaatar districts of 17.7% (95% CI: 15.2-20.4) (Table 9). Out of 150 unregistered samples, 18 were substandard (12.0%), compared with 94 substandard samples out of the 698 registered samples (13.5%). This difference is not statistically significant ( $p = 0.6$ ) (Table 10).

#### Discussion

Our results provide prevalence estimates for substandard drugs in Mongolia of 17.8% in the rural provinces and 13.2% in the urban districts of Ulaanbaatar, based on

failure to meet the threshold quality standards established in the selected Pharmacopeia. While our study design does not allow us to directly compare these results from these 2 regions, it is interesting to note a modestly higher prevalence of substandard drugs in the rural sample. We also noted a significant association between substandard and unregistered drugs in the provinces, but not in the urban districts.

Our prevalence estimates of substandard drugs of 17.8% and 13.2% in Mongolia are in alignment with the range of 11-14% reported by Almuzaini et al. in their recent review of substandard and falsified medications in low and middle income countries in Asia and Africa (Almuzaini et al. 2013). Our prevalence estimates are lower than the median percentage of 28% reported in this review, however, this comparison is limited by the differences in methodology, sample size, inclusion criteria and drugs selected between the various studies reported and ours. The most common reason for a sample to be substandard was failure to pass assay test, which is consistent with the findings of other studies (Almuzaini et al. 2013). Failure to pass the assay test, along with failure to pass the disintegration and dissolution tests, the other most common reasons in our study, indicates that the bioavailability of the active ingredients was compromised. This can lead to ineffective treatment, and in the case of antibiotics, promote drug resistance. Of note, almost none of the samples were found to be post-expiration date, suggesting other factors are contributing to the degradation in drug quality. Further investigation into drug transport and storage conditions may help better understand this, especially given the extreme weather conditions found in Mongolia.

Another interesting finding of our study was the 21.9% prevalence of unregistered drugs in the provinces and 17.7% in the districts of Ulaanbaatar. This raises the importance of further investigation of the drug supply chain and evaluation of drug regulatory policies. Such initiatives could be undertaken at the national level and through collaborations with neighboring countries. We believe this may be an especially important step to improve the quality of the drug supply in the provinces where there was a statistically significant association between unregistered and substandard drug samples.

An adequate sample size is essential to obtaining valid results. Our sample size calculations indicated that we would need 342 samples for each region to detect a 15% prevalence. We achieved this in both the rural provinces (N = 388, 17.8% prevalence) and the urban districts (N = 848, 13.2% prevalence). However, there are some weaknesses in our study that could underestimate our prevalence estimates. These include the potential for drug outlet personnel to selectively provide drugs if they were suspicious about the reason for the purchase, and

**Table 6 Sample analysis for drugs by acceptability from rural provinces**

	Amoxicillin		Ampicillin		Bromhexin		Co-trimoxazole		Doxycycline		Ibuprofen		Metronidazole		Nystatin		Paracetamol		Total		
	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	
<b>Not acceptable</b>																					
Assay	2	1%	0	0%	0	0%	6	2%	4	1%	11	4%	17	6%	7	3%	4	2%	51	2%	
Disintegration	0	0%	0	0%	0	0%	1	0%	0	0%	5	2%	1	0%	0	0%	0	0%	7	0%	
Dissolution	1	0%	0	0%	0	0%	0	0%	0	0%	5	2%	2	1%	0	0%	3	1%	11	0%	
Friction	0	0%	0	0%	0	0%	5	1%	0	0%	0	0%	0	0%	0	0%	0	0%	5	0%	
Wt average	0	0%	0	0%	0	0%	1	0%	0	0%	0	0%	15	5%	0	0%	0	0%	16	1%	
Wt variation	1	0%	0	0%	0	0%	3	1%	1	0%	5	2%	12	4%	0	0%	5	2%	27	1%	
<b>Not acceptable total</b>	<b>4</b>	<b>1%</b>	<b>0</b>	<b>0%</b>	<b>0</b>	<b>0%</b>	<b>16</b>	<b>5%</b>	<b>5</b>	<b>2%</b>	<b>26</b>	<b>9%</b>	<b>47</b>	<b>16%</b>	<b>7</b>	<b>3%</b>	<b>12</b>	<b>5%</b>	<b>117</b>	<b>4%</b>	
<b>Acceptable</b>																					
Appearance	46	14%	40	14%	41	17%	47	14%	43	14%	43	14%	41	14%	49	17%	38	14%	388	15%	
Assay	44	13%	40	14%	41	17%	41	12%	39	13%	32	11%	24	8%	42	14%	34	13%	337	13%	
Disintegration	46	14%	40	14%	41	17%	46	14%	43	14%	38	13%	40	14%	49	17%	38	14%	381	14%	
Dissolution	45	14%	40	14%	2	1%	5	1%	43	14%	38	13%	39	14%	0	0%	35	13%	247	9%	
Friction	0	0%	0	0%	0	0%	40	12%	0	0%	0	0%	0	0%	0	0%	0	0%	40	2%	
Identification	46	14%	40	14%	41	17%	47	14%	43	14%	43	14%	41	14%	49	17%	38	14%	388	15%	
Irradiance absorption	0	0%	0	0%	0	0%	0	0%	5	2%	0	0%	0	0%	0	0%	0	0%	5	0%	
Substantial	0	0%	0	0%	0	0%	2	1%	0	0%	0	0%	0	0%	0	0%	0	0%	2	0%	
Water	4	1%	0	0%	0	0%	0	0%	0	0%	0	0%	0	0%	0	0%	0	0%	4	0%	
Wt average	46	14%	40	14%	41	17%	46	14%	43	14%	43	14%	26	9%	49	17%	38	14%	372	14%	
Wt variation	45	14%	40	14%	41	17%	44	13%	42	14%	38	13%	29	10%	49	17%	33	12%	361	14%	
<b>Acceptable total</b>	<b>322</b>	<b>99%</b>	<b>280</b>	<b>100%</b>	<b>248</b>	<b>100%</b>	<b>318</b>	<b>95%</b>	<b>301</b>	<b>98%</b>	<b>275</b>	<b>91%</b>	<b>240</b>	<b>84%</b>	<b>287</b>	<b>97%</b>	<b>254</b>	<b>95%</b>	<b>2525</b>	<b>96%</b>	
<b>Grand total</b>	<b>326</b>	<b>100%</b>	<b>280</b>	<b>100%</b>	<b>248</b>	<b>100%</b>	<b>334</b>	<b>100%</b>	<b>306</b>	<b>100%</b>	<b>301</b>	<b>100%</b>	<b>287</b>	<b>100%</b>	<b>294</b>	<b>100%</b>	<b>266</b>	<b>100%</b>	<b>2642</b>	<b>100%</b>	

**Table 7 Sample analysis for drugs by acceptability from urban districts**

	Amoxicillin		Ampicillin		Bromhexin		Co-trimoxazole		Doxycycline		Ibuprofen		Metronidazole		Nystatin		Paracetamol		Total		
	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	
<b>Not Acceptable</b>																					
Assay	9	1%	0	0%	0	0%	0	0%	8	1%	8	1%	6	1%	23	4%	1	0%	55	1%	
Disintegration	0	0%	0	0%	0	0%	2	0%	0	0%	36	5%	0	0%	0	0%	6	1%	44	1%	
Dissolution	0	0%	0	0%	0	0%	1	0%	1	0%	8	1%	5	1%	0	0%	5	1%	20	0%	
Friction	0	0%	0	0%	0	0%	0	0%	0	0%	1	0%	0	0%	0	0%	0	0%	1	0%	
Wt Average	0	0%	0	0%	0	0%	0	0%	0	0%	0	0%	3	0%	0	0%	0	0%	3	0%	
Wt Variation	2	0%	0	0%	0	0%	0	0%	7	1%	2	0%	3	0%	0	0%	1	0%	15	0%	
<b>Not Acceptable Total</b>	<b>11</b>	<b>2%</b>	<b>0</b>	<b>0%</b>	<b>0</b>	<b>0%</b>	<b>3</b>	<b>0%</b>	<b>16</b>	<b>3%</b>	<b>55</b>	<b>8%</b>	<b>17</b>	<b>2%</b>	<b>23</b>	<b>4%</b>	<b>13</b>	<b>3%</b>	<b>138</b>	<b>2%</b>	
<b>Acceptable</b>																					
Appearance	101	14%	94	14%	105	14%	95	13%	83	14%	95	13%	109	14%	100	17%	65	14%	848	14%	
Assay	92	13%	94	14%	106	14%	95	13%	75	13%	87	12%	103	13%	78	13%	64	14%	793	13%	
Disintegration	101	14%	94	14%	106	14%	91	12%	83	14%	59	8%	109	14%	100	17%	59	13%	802	13%	
Dissolution	101	14%	94	14%	2	0%	93	12%	82	14%	86	12%	101	13%	2	0%	58	13%	619	10%	
Friction	1	0%	0	0%	104	14%	94	12%	1	0%	62	9%	3	0%	1	0%	0	0%	266	4%	
Identification	101	14%	94	14%	106	14%	95	13%	83	14%	95	13%	109	14%	100	17%	65	14%	848	14%	
Wt Average	101	14%	94	14%	106	14%	95	13%	83	14%	95	13%	106	14%	100	17%	65	14%	845	14%	
Wt Variation	99	14%	94	14%	106	14%	95	13%	76	13%	93	13%	106	14%	100	17%	64	14%	833	14%	
<b>Total Acceptable</b>	<b>697</b>	<b>98%</b>	<b>658</b>	<b>100%</b>	<b>742</b>	<b>100%</b>	<b>753</b>	<b>100%</b>	<b>566</b>	<b>97%</b>	<b>672</b>	<b>92%</b>	<b>746</b>	<b>98%</b>	<b>581</b>	<b>96%</b>	<b>440</b>	<b>97%</b>	<b>5854</b>	<b>98%</b>	
<b>Grand Total</b>	<b>708</b>	<b>100%</b>	<b>658</b>	<b>100%</b>	<b>742</b>	<b>100%</b>	<b>756</b>	<b>100%</b>	<b>582</b>	<b>100%</b>	<b>727</b>	<b>100%</b>	<b>763</b>	<b>100%</b>	<b>603</b>	<b>100%</b>	<b>453</b>	<b>100%</b>	<b>5992</b>	<b>100%</b>	